Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Cation-π interactions in protein-ligand binding: theory and data-mining reveal different roles for lysine and arginine.

Kumar K, Woo SM, Siu T, Cortopassi WA, Duarte F, Paton RS.

Chem Sci. 2018 Jan 31;9(10):2655-2665. doi: 10.1039/c7sc04905f. eCollection 2018 Mar 14.

2.

Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23.

Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N.

Structure. 2018 Feb 6;26(2):270-281.e4. doi: 10.1016/j.str.2017.12.012. Epub 2018 Jan 18.

PMID:
29358026
3.

SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase.

Knittle AM, Helkkula M, Johnson MS, Sundvall M, Elenius K.

J Biol Chem. 2017 Dec 1;292(48):19890-19904. doi: 10.1074/jbc.M117.794271. Epub 2017 Oct 3.

PMID:
28974580
4.

EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.

van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2836-E2845. doi: 10.1073/pnas.1617994114. Epub 2017 Mar 20.

5.

The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.

Kennedy SP, Hastings JF, Han JZ, Croucher DR.

Front Cell Dev Biol. 2016 Aug 22;4:88. doi: 10.3389/fcell.2016.00088. eCollection 2016. Review.

6.

Molecular basis for multimerization in the activation of the epidermal growth factor receptor.

Huang Y, Bharill S, Karandur D, Peterson SM, Marita M, Shi X, Kaliszewski MJ, Smith AW, Isacoff EY, Kuriyan J.

Elife. 2016 Mar 28;5. pii: e14107. doi: 10.7554/eLife.14107.

7.

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.

Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, Tesei A.

Oncotarget. 2016 Apr 5;7(14):18424-39. doi: 10.18632/oncotarget.7575.

8.

Prognostic value of ERBB4 expression in patients with triple negative breast cancer.

Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH.

BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.

9.

Structural Basis for the Non-catalytic Functions of Protein Kinases.

Kung JE, Jura N.

Structure. 2016 Jan 5;24(1):7-24. doi: 10.1016/j.str.2015.10.020. Review.

10.

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C.

Nat Commun. 2015 Nov 4;6:8760. doi: 10.1038/ncomms9760.

11.

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.

Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L.

Drug Des Devel Ther. 2015 Jul 23;9:3837-51. doi: 10.2147/DDDT.S85357. eCollection 2015.

12.
13.

Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.

Ravichandran S, Luke BT, Collins JR.

J Mol Graph Model. 2015 Apr;57:36-48. doi: 10.1016/j.jmgm.2014.12.007. Epub 2015 Jan 12.

14.

A structural perspective on the regulation of the epidermal growth factor receptor.

Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J.

Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402. Epub 2015 Jan 26. Review.

15.

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.

Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N.

Sci Signal. 2014 Dec 2;7(354):ra114. doi: 10.1126/scisignal.2005786.

16.

Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.

Ward MD, Leahy DJ.

J Biol Chem. 2015 Jan 16;290(3):1570-9. doi: 10.1074/jbc.M114.612085. Epub 2014 Dec 2.

19.

Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.

Macdonald-Obermann JL, Pike LJ.

J Biol Chem. 2014 Sep 19;289(38):26178-88. doi: 10.1074/jbc.M114.586826. Epub 2014 Aug 1.

20.

Structure-functional prediction and analysis of cancer mutation effects in protein kinases.

Dixit A, Verkhivker GM.

Comput Math Methods Med. 2014;2014:653487. doi: 10.1155/2014/653487. Epub 2014 Apr 8.

Supplemental Content

Support Center